Role of interleukin‐1β in NLRP12‐associated autoinflammatory disorders and resistance to anti–interleukin‐1 therapy

• Published in: Arthritis & rheumatology (Hoboken, N.J.) Vol. 63; no. 7; pp. 2142 - 2148
• Main Authors: Jéru, Isabelle, Hentgen, Véronique, Normand, Sylvain, Duquesnoy, Philippe, Cochet, Emmanuelle, Delwail, Adriana, Grateau, Gilles, Marlin, Sandrine, Amselem, Serge, Lecron, Jean‐Claude
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2011; Wiley
• Subjects: Biological and medical sciences; Diseases of the osteoarticular system; Enzyme-Linked Immunosorbent Assay; Genetics; Hereditary Autoinflammatory Diseases - drug therapy; Hereditary Autoinflammatory Diseases - genetics; Hereditary Autoinflammatory Diseases - immunology; Humans; Immunology; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Interleukin-1beta - metabolism; Intracellular Signaling Peptides and Proteins - genetics; Life Sciences; Male; Medical sciences; Prospective Studies; Signal Transduction; Resistance; Interleukin 1β; Treatment; Interleukin 1; Rheumatology

Objective A new class of autoinflammatory syndromes called NLRP12‐associated disorders (NLRP12AD) has been associated with mutations in NLRP12. Conflicting data on the putative role of NLRP12 in interleukin‐1β (IL‐1β) signaling have been found in in vitro analyses. This prospective study was underta...